Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carotid stenting

This article was originally published in The Gray Sheet

Executive Summary

In a Sept. 10 1proposal, CMS signals plans to once again decline to expand the Medicare covered population for carotid artery stenting, despite data published since two prior reconsiderations in 2007 and 2008. The agency opened a coverage analysis in March on its own initiative after new data was published by carotid stent makers Johnson & Johnson and Abbott, sparking hopes in the interventional cardiology community that a larger proportion of patients included in FDA-approved labeling would be covered, in particular patients with significant arterial blockage, but no symptoms (2"The Gray Sheet" March 23, 2009). Ultimately, CMS found that the "evidence base for carotid artery stenting continues to be of lower quality." A final decision is expected in December
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT027895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel